NCI-2018-00514, NCT03502577: BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma |
|
|
| Terminated | 1 | 19 | US | BCMA-specific CAR-expressing T Lymphocytes, Anti-BCMA CAR T Cells, Anti-BCMA-CAR-transduced T Cells, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Gamma-Secretase Inhibitor LY3039478, LY 3039478, LY-3039478, LY3039478, JSMD194, Laboratory Biomarker Analysis, Pharmacokinetic Study, PHARMACOKINETIC, PK Study | Fred Hutchinson Cancer Center, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, The Leukemia and Lymphoma Society | Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | 04/22 | 04/22 | | |
